Anya Biopharm (ROCO:7776) LT-Debt-to-Total-Asset: 0.01 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7776 Anya Biopharm Inc ROCO:7776
12 GF Score
Price NT$33.35
! 4 Warning Signs
View Full Analysis

What is Anya Biopharm LT-Debt-to-Total-Asset?

Anya Biopharm ROCO:7776 +0.15% 12 LT-Debt-to-Total-Asset is 0.01 as of Dec. 2025. GuruFocus rates ROCO:7776 with a GF Score™ of 12/100. The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Anya Biopharm's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.01.

Anya Biopharm's long-term debt to total assets ratio stayed the same from Dec. 2024 (0.01) to Dec. 2025 (0.01).

Anya Biopharm  (ROCO:7776) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Anya Biopharm LT-Debt-to-Total-Asset Related Terms

Anya Biopharm LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Anya Biopharm's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anya Biopharm LT-Debt-to-Total-Asset Chart

Anya Biopharm Annual Data
Trend Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
0.08 0.00 0.01 0.01

Anya Biopharm Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial 0.00 0.01 0.01 0.01 0.01
ROCO:7776
12GF Score
Anya Biopharm Inc ROCO:7776
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anya Biopharm LT-Debt-to-Total-Asset Calculation

Anya Biopharm's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=2.833/413.871
=0.01

Anya Biopharm's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=2.833/413.871
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.01 mean?
Anya Biopharm (ROCO:7776) has a LT-Debt-to-Total-Asset of 0.01 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Anya Biopharm and its competitors.
Is Anya Biopharm's LT-Debt-to-Total-Asset too high?
Anya Biopharm's current LT-Debt-to-Total-Asset is 0.01. Overall, Anya Biopharm has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Anya Biopharm's LT-Debt-to-Total-Asset compare to VRTX and REGN?
Anya Biopharm's LT-Debt-to-Total-Asset of 0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Anya Biopharm and its competitors. Anya Biopharm's current LT-Debt-to-Total-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anya Biopharm stock overvalued right now?
Anya Biopharm (ROCO:7776) has a current LT-Debt-to-Total-Asset of 0.01. The current LT-Debt-to-Total-Asset is 0.01. Anya Biopharm's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Anya Biopharm (ROCO:7776), the current LT-Debt-to-Total-Asset is 0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anya Biopharm Business Description

Address No. 3-2, Yuanqu Street, 4th Floor, Nangang, Taipei, TWN, 115603
Anya Biopharm Inc is a pharmaceutical company engaged in the Oral Delivery of Peptides. Its patented technology platform Mira/Je is a flexible solution easy to adapt to a large variety of peptides.
12GF Score

Get the complete analysis for ROCO:7776

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$33.35
Price